SAGE Sage Therapeutics Inc: Price-to-Projected Revenue Ratio

Official company branding of Sage Therapeutics (SAGE)

Sage Therapeutics, Inc. (SAGE) relies on contract manufacturers for drug production while maintaining strict internal quality control. The issuer's forward P/S reflects the business valuation trend, with the current level sitting around 7.80. While loyalty from neurology experts previously drove scientific progress, the company is currently reducing headcount following unsuccessful trials, utilizing stock options to retain key scientists.

Sage Therapeutics - SAGE Forward P/S Multiple (period 07/04/2022 - 08/16/2025)

SAGE (Sage Therapeutics): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company analysis:Sage Therapeutics (SAGE)
Product sample of sagerx.com

Investors are evaluating Sage Therapeutics, Inc. (SAGE) through the lens of the slow adoption of its depression drug and risks associated with Alzheimer's research, which renders revenue volatile. The forward revenue multiple on GURU.Markets compares current market capitalization with expected annual sales, allowing for a determination of whether the market is overpaying for future growth amid the company's limited cash reserves.

Competing companies

Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cyclerion.com CYCN|Forward P/S Multiple PTIX|KTTA - Market Cap to Future Revenue Ratio|Forward P/S Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics Inc (ATXI) - Market Cap to Future Revenue Ratio|BCLI - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio caratherapeutics.com|CHRO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Eliem Therapeutics (ELYM)|ITCI (Intra-Cellular Therapies Inc.) - Forward P/S Multiple|Forward P/S Multiple Longboard|Forward P/S Multiple MRNS|Market Cap to Expected Sales Ratio nkgenbiotech.com|Forward P/S Multiple NRBO (neurobopharma.com)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple